Fundz

Aim Immuno Tech reported raising $3.3 Million in an initial SEC Form D filing, from an offering of $3.3 Million

PUBLIC · AIMFeb 20, 2024

Amount Raised

$3.3 Million

$3.3 Million sold, per SEC Form D (first sale Feb 16, 2024)

Round Type

Seed

OcalaBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as AIM ImmunoTech that raised within 45 days of this round, from Fundz verified event records.

  • Azora Therapeutics, Inc. (DE) raised $288K (Seed) on March 6, 2024.
  • Crinetics Pharmaceuticals raised $350M on March 1, 2024.
  • Parabilis Medicines raised $145M (Series E) on March 1, 2024.
  • vTv Therapeutics Inc. raised $51M on February 27, 2024.
  • Biofrontera raised $8M on February 19, 2024.
  • Vaccinex raised $1.8M (Seed) on March 29, 2024.

Who to call at AIM ImmunoTech, and when

A new round usually means AIM ImmunoTech is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AIM ImmunoTech raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AIM ImmunoTech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AIM ImmunoTech. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AIM ImmunoTech

Location

Ocala, Florida, United States

About

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AIM ImmunoTech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

5 contacts
Verified contactsDavid C., Member Board of Directors hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for AIM ImmunoTech's next move

See what Strategic adds

AIM ImmunoTech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.